On the stock market since 2020, it operates in the world of health and science. It has 99 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Average growth of 57% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
Business Quality: Profit power and business quality trail similar companies in the sector.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Executive Buying: The trades send no strong signal of confidence.
An investor who bought at the very peak is down 72% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 3 years, sales grew about 57% a year on average.
Sales run at $9.8M a year. A small number, but proof the product has real buyers.
There is $319.8M in the vault; even if every debt were paid off, $301.6M would remain.
A loss of $109.0M against $9.8M in annual sales.
Measured against its sector, the quality of the business sits below the class average. Report-card grade: 21/100.
Today’s price already includes part of tomorrow’s optimism. Report-card grade: 41/100.
On our five-subject report card, TSHA sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: TSHA is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (41/100) says the stock isn’t cheap.